Actively Recruiting
Study of Toripalimab Plus Actinomycin-D as First Treatment for Women with Gestational Trophoblastic Neoplasia and FIGO Score 7 Phase II, Single-Arm Trial Evaluating Effectiveness and Safety
Led by Peking Union Medical College Hospital · Updated on 2024-12-31
17
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial investigates the use of toripalimab combined with actinomycin-D as the first treatment for women diagnosed with gestational trophoblastic neoplasia GTN who have a FIGO score of 7. The main goal is to see if this combination can achieve a high rate of complete remission and to evaluate if patients who do not respond can be successfully treated with multi-drug chemotherapy as a second option. The study is a phase II, multicenter trial focused on safety and effectiveness in this specific patient group. Participants will receive toripalimab at a dose of 200mg intravenously every two weeks along with actinomycin-D at 1.25mgm2 up to 2mg maximum intravenously every two weeks. Treatment continues until the disease progresses, unacceptable side effects occur, or consent is withdrawn. After serum beta-human chorionic gonadotropin b2-hCG levels normalize, patients will receive four cycles of consolidation treatment to complete the therapy. During the study, participants will have regular assessments including blood tests to monitor b2-hCG levels, organ function, and ovarian function, along with evaluations of quality of life and cancer-specific rehabilitation needs. Researchers will measure outcomes such as complete remission rate, objective response rate, progression-free survival, overall survival, duration of response, safety, and reproductive concerns. Follow-up and monitoring will occur up to one year after treatment to evaluate these outcomes.
CONDITIONS
Brief Title
Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7
Research Team
Y
Yang Xiang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here